Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
Ligand Pharmaceuticals (NASDAQ: LGND) stock skyrocketed earlier this year. However, the short squeeze that fueled those massive gains is now over. That means that Ligand probably needs a more conventional catalyst to go on another run.
The company announced its first-quarter results after the market closed on Monday. Don't expect those results to provide the catalyst investors wanted. The biotech stock fell more than 6% in after-hours trading. Here are the highlights from Ligand's Q1 update.
Image source: Getty Images.
Source Fool.com
